GeorgePapakostasMD
Psychiatry • Boston, MAProfessor at Harvard Medical School and Associate Executive Director, Clinical Trials Network and Institute, Massachusetts General Hospital.
Dr. Papakostas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
S50 4 Massachusetts General Hospital
Boston, MA 02114Phone+1 617-726-6697Fax+1 617-726-2894
Education & Training
Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1999 - 2002
Steward Carney HospitalInternship, Internal Medicine, 1998 - 1999
New York University School of MedicineClass of 1998
Certifications & Licensure
MA State Medical License 2002 - 2026- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression Start of enrollment: 2004 May 01
- A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD) Start of enrollment: 2006 Nov 01
- A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder Start of enrollment: 2008 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsComparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial.George I Papakostas, Madhukar H Trivedi, Richard C Shelton, Dan V Iosifescu, Michael E Thase
Molecular Psychiatry. 2024-08-01 - 1 citationsAntidepressants in the acute treatment of post-traumatic stress disorder in adults: a systematic review and meta-analysis.Clotilde Guidetti, Anna Feeney, Rebecca S Hock, Nadia Iovieno, Jesús M Hernández Ortiz
International Clinical Psychopharmacology. 2024-06-14 - 6 citationsPharmacotherapy: Ketamine and Esketamine.Anna Feeney, George I Papakostas
The Psychiatric Clinics of North America. 2023-06-01
Journal Articles
- Research Paper Tachyphylaxis in Major Depressive Disorder: A Review of the Current State of ResearchGustavo Kinrys, Andrew A Nierenberg, George I Papakostas, David Mischoulon, Maurizio Fava, Marlene P Freeman, ScienceDirect
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Press Mentions
4 Serotonin Supplements to Treat Depression, Anxiety, & Insomnia YourselfJune 5th, 2019
Allergan’s Phase III Botox Trial for Depression Pushed to H2 2019December 10th, 2018- Major Depression ZiprasidoneOctober 6th, 2017
- Join now to see all
Grant Support
- 1/2-Ziprasidone Augmentation Of Ssris For Treatment-Resistant Depression (TRD)National Institute Of Mental Health2008–2012
- S-Adenosyl Methionine(Same)Augmentation Of Ssris In MDDNational Institute Of Mental Health2004–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
